Amarin's Vascepa drug had initial commercial success but is now facing steep revenue declines due to generic competition and limited U.S. market adoption. The company is running sizable losses, with ...
Amarin is transforming Vascepa from a declining U.S. business into a global cardiovascular growth story, driven by disciplined expense control and strategic partnerships. AMRN's European and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results